KABLA COMERCIAL supplier risk profile Q1 2026: 430 shipments, China-dominant sourcing, A-grade assessment.
KABLA COMERCIAL imported 430 shipments across 35 suppliers in Q1 2026, sourcing from 11 countries with China accounting for 61% of volume. The importer's supply chain centers on Chapter 38 products (organic chemicals and related compounds), which represent 61% of shipments, led by HS code 382219. Top supplier SHENZHEN NEW BIOMEDICAL ENGINEERING supplied 134 shipments, with HANGZHOU ALLTEST BIOTECH and CARETIUM MEDICAL INSTRUMENTS also among primary sources from mainland China.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name in the importer's supply chain matched a sanctions watchlist. No suppliers registered forced-labor exposure under UFLPA-linked factory databases.
35 distinct tier-1 suppliers in Q1 2026
| SHENZHEN NEW BIOMEDICAL ENGINEERING | China | 134 |
| HANGZHOU ALLTEST BIOTECH | China | 35 |
| CARETIUM MEDICAL INSTRUMENTS | China | 31 |
| CERTEST BIOTEC SL | Spain | 19 |
| VIRCELL S L | Spain | 16 |
| AVE SCIENCE TECHNOLOGY | China | 16 |
| ACCUMAX LAB DEVICES PRIVATE SEZ | India | 14 |
| RESPONSE BIOMEDICAL | Canada | 13 |
Share of Q1 2026 inbound shipments by source country
64 tier-2 + 22 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.